The US Food and Drug Administration (FDA) has granted fast-track designation for Stealth BioTherapeutics’ lead candidate, elamipretide, to treat patients with Barth syndrome.

Barth syndrome is a rare genetic mitochondrial disease caused by mutations in the Tafazzin (TAZ) gene and results in skeletal muscle weakness, cardiac abnormalities that often lead to heart failure, recurrent infections, delayed growth and reduced life expectancy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

There are currently no FDA-approved therapies available for the disease.

Stealth BioTherapeutics CEO Reenie McCarthy said: “Fast-track designation is an important milestone which will facilitate Stealth’s efforts to develop an effective treatment for the Barth syndrome patient community, for whom there are currently no FDA-approved therapies.

“Fast-track designation is an important milestone which will facilitate Stealth’s efforts to develop an effective treatment for the Barth syndrome patient community.”

“We are committed to developing treatments for patients suffering from rare mitochondrial diseases such as Barth syndrome, and look forward to working closely with the FDA in addressing this critical unmet need.”

The designation supports the development and review of new therapies that can be potentially used to treat serious conditions with unmet medical needs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In July this year, the biopharmaceutical company initiated a randomised, double-blind, placebo-controlled, crossover Phase II / III TAZPOWER study that would evaluate the effects of daily use of elamipretide in patients with genetically confirmed Barth syndrome.

Top-line results from the study are expected next year.

In December 2015, Stealth’s elamipretide was granted fast-track status for the treatment of primary mitochondrial myopathy (PMM), another form of rare mitochondrial disease.